LYAR: A Potential Drug Target and Biomarker (G55646)

Target Name: LYAR

NCBI ID: G55646

LYAR

LYAR: A Potential Drug Target and Biomarker

LYAR (Ly1 antibody reactive) is a protein that is expressed in a variety of tissues, including the brain, spleen, heart, and testes. It is a member of the Ly family of proteins, which are known for their role in cell signaling and inflammation. LYAR is a 21-kDa antibody reactive protein that is expressed in a variety of tissues, including the brain, spleen, heart, and testes. It is a member of the Ly family of proteins, which are known for their role in cell signaling and inflammation.

Recent studies have identified LYAR as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LYAR has also been shown to play a role in several diseases, including neurofibromatosis and chronic myeloid leukemia.

One of the key advantages of LYAR is its expression in a variety of tissues, which makes it an attractive target for drugs that can be administered to a wide range of patients. Additionally, LYAR is a small protein that is expressed in a low abundance, which makes it difficult to generate false positives when it is used for diagnostic purposes.

In addition to its potential as a drug target, LYAR has also been shown to be a potential biomarker for several diseases. For example, LYAR has been shown to be elevated in the brains of patients with neurofibromatosis, a genetic disorder that causes tumors to grow on the brain. Additionally, LYAR has been shown to be elevated in the blood of patients with chronic myeloid leukemia, a type of cancer that affects the bone marrow.

Another promising aspect of LYAR is its ability to be targeted with small molecules. LYAR is a small protein that is expressed in a low abundance, which makes it difficult to generate false positives when it is used for diagnostic purposes. This makes it an attractive target for small molecules that can be used to modulate its expression.

LYAR has also been shown to play a role in several diseases, including neurofibromatosis and chronic myeloid leukemia. In neurofibromatosis, LYAR is expressed in the brains of patients and has been shown to be involved in the development and progression of the disease. In chronic myeloid leukemia, LYAR has been shown to be expressed in the blood and has been shown to play a role in the development and progression of the disease.

In conclusion, LYAR is a protein that is expressed in a variety of tissues and has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression in a variety of tissues and its ability to be targeted with small molecules make it an attractive target for drugs and biomarkers. Further studies are needed to fully understand the role of LYAR in disease and to develop effective treatments.

Protein Name: Ly1 Antibody Reactive

Functions: Plays a role in the maintenance of the appropriate processing of 47S/45S pre-rRNA to 32S/30S pre-rRNAs and their subsequent processing to produce 18S and 28S rRNAs (PubMed:24495227). Also acts at the level of transcription regulation. Along with PRMT5, binds the gamma-globin (HBG1/HBG2) promoter and represses its expression (PubMed:25092918). In neuroblastoma cells, may also repress the expression of oxidative stress genes, including CHAC1, HMOX1, SLC7A11, ULBP1 and SNORD41 that encodes a small nucleolar RNA (PubMed:28686580). Preferentially binds to a DNA motif containing 5'-GGTTAT-3' (PubMed:25092918). Negatively regulates the antiviral innate immune response by targeting IRF3 and impairing its DNA-binding activity (PubMed:31413131). In addition, inhibits NF-kappa-B-mediated expression of pro-inflammatory cytokines (PubMed:31413131). Stimulates phagocytosis of photoreceptor outer segments by retinal pigment epithelial cells (By similarity). Prevents nucleolin/NCL self-cleavage, maintaining a normal steady-state level of NCL protein in undifferentiated embryonic stem cells (ESCs), which in turn is essential for ESC self-renewal (By similarity)

The "LYAR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYAR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets